Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Berlex Biosciences

Division of Bayer AG

Latest From Berlex Biosciences

Appointments: Avillion, X4 Pharmaceuticals, Summit, Cytovation, Kymab, Ipsen and Sosei

This week's roundup includes the appointments of chief medical officers by both Avillion and X4 Pharmaceuticals and various other senior appointments at Summit Therapeutics, Sosei, Ipsen and Kymab.

Appointments BioPharmaceutical

Bayer Expands Its Chinese R&D Network With Peking University Joint Research Center

Bayer HealthCare signed a deal with Peking University to establish a joint research center in Beijing to strengthen its R&D capability in China.

BioPharmaceutical China

Deals Shaping the Medical Industry (11/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Exelixis: Bartering for Growth

This genomics-based company has used business development as a strategic tool, swapping for key capacities that have helped it quickly leap forward. As the company demonstrated the merits of its model-organism platform, it began asking partners not for the most money they would give--but for assets that would help it forward integrate. One deal that started small expanded into a life-changing technology swap: from BMS, Exelixis got combinatorial chemistry capacity that it can now use to make compounds against its own targets. It also got a Phase II drug candidate for cancer, and rights to half of the molecules it makes for BMS, and Exelixis has used its new chemistry capacity to sign other barter-driven deals. Rapid evolution has risks: unless Exelixis accesses other fairly mature drug candidates, there will be a gap between launch of its first product and other compounds that haven't been tried yet in humans.
See All

Company Information